By Ian Walker

Pharmaceutical company AstraZeneca PLC (AZN.LN) said Thursday that Aspen Group's (APZ.AU) unit will buy the remaining rights to its anesthetic medicines for up to $766 million.

Following the initial deal entered into in June 2016--which saw Aspen Global Incorporated gain exclusive commercialization rights to the medicines in markets outside the U.S.--Aspen Global will now buy the remaining rights to Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.

It is paying an initial $555 million for the remaining rights to the intellectual property and manufacturing knowledge related to the anesthetic medicines, plus a further $211 million based on performance.

AstraZeneca said it will continue to manufacture and supply the medicines to Aspen Global during a transition period of up to five years.

Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

(END) Dow Jones Newswires

September 14, 2017 02:41 ET (06:41 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Aspen (ASX:APZ)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Aspen Charts.
Aspen (ASX:APZ)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Aspen Charts.